Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:14:13 EDT Sun 11 Oct 2026
Enter Symbol
or Name
USA
CA



Q:GILD - GILEAD SCIENCES INC - https://www.gilead.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
GILD - Q0.2151.00·151.201.5151.17+4.072.85,802.2871,66145,113147.23  151.44  146.10157.27  114.0219:50:33Sep 1615 min RT 2¢

Recent Trades - Last 10 of 45113
Time ETExPriceChangeVolume
19:50:33Q151.204.1025
19:36:56Q151.444.343
19:30:05Q151.20084.10081
19:30:05Q151.20084.10081
19:30:04Q151.20084.10081
19:30:04Q151.20084.10081
19:30:03Q151.20084.10081
19:30:03Q151.20084.10081
18:59:54Q151.20084.1008125
18:53:28Q151.254.1510

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-09-16 08:30U:GILDNews ReleaseGilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
2026-09-15 11:10U:GILDNews ReleaseGilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
2026-09-15 09:00U:GILDNews ReleaseA $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
2026-09-08 13:00U:GILDNews ReleaseGilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
2026-08-27 17:47U:GILDNews ReleaseU.S. FDA Approves Gilead's Bixlenvo(TM), a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
2026-08-26 16:05U:GILDNews ReleaseGilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
2026-08-24 06:31U:GILDNews ReleaseEuropean Commission Expands Role of Gilead's Trodelvy(TM) in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
2026-08-04 13:01U:GILDNews ReleaseCORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
2026-07-24 06:26U:GILDNews ReleaseCHMP Recommends Gilead's Trodelvy(TM) Plus Keytruda(TM) in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
2026-07-21 16:05U:GILDNews ReleaseGilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
2026-07-21 10:00U:GILDNews ReleaseInvestigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
2026-07-21 10:00U:GILDNews ReleaseGilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
2026-06-24 16:29U:GILDNews ReleaseU.S. FDA Approves Trodelvy(TM) for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
2026-06-24 08:30U:GILDNews ReleaseNext-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
2026-06-23 07:45U:GILDNews ReleaseEuropean Commission Approves Trodelvy(TM) as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
2026-06-15 16:34U:GILDNews ReleaseU.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
2026-06-12 08:30U:GILDNews ReleaseGilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
2026-06-11 08:30U:GILDNews ReleaseNational AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
2026-06-08 16:35U:GILDNews ReleaseGilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
2026-06-08 16:30U:GILDNews ReleaseMerck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study